4.7 Article

Isothiocyanates (ITCs) 1-(Isothiocyanatomethyl)-4-phenylbenzene and 1-Isothiocyanato-3,5-bis(trifluoromethyl)benzene-Aldehyde Dehydrogenase (ALDH) Inhibitors, Decreases Cisplatin Tolerance and Migratory Ability of NSCLC

Journal

Publisher

MDPI
DOI: 10.3390/ijms23158644

Keywords

non-small-cell lung cancer; cisplatin resistance; aldehyde dehydrogenase; isothiocyanates; disulfiram; epithelial to mesenchymal transition

Funding

  1. National Center for Research and Development (Warsaw, Poland) [POWR.03.02.00-00-I029/16]
  2. Medical University of Lodz [503/1-013-02/503-11-001-19-00]

Ask authors/readers for more resources

One of the main challenges in the treatment of non-small-cell lung cancer is the development of resistance to cisplatin-based chemotherapy. This study investigates the potential of isothiocyanates (ITCs) and the ALDH inhibitor disulfiram (DSF) as adjuvants to cisplatin chemotherapy. The results show that certain ITCs and DSF can reduce the cisplatin tolerance of resistant lung cancer cells, suggesting their potential in overcoming drug resistance.
One of the main treatment modalities for non-small-cell lung cancer (NSCLC) is cisplatin-based chemotherapy. However, the acquisition of cisplatin resistance remains a major problem. Existing chemotherapy regimens are often ineffective against cancer cells expressing aldehyde dehydrogenase (ALDH). As such, there is an urgent need for therapies targeting ALDH-positive cancer cells. The present study compares the anticancer properties of 36 structurally diverse isothiocyanates (ITCs) against NSCLC cells with the ALDH inhibitor disulfiram (DSF). Their potential affinity to ALDH isoforms and ABC proteins was assessed using AutoDockTools, allowing for selection of three compounds presenting the strongest affinity to all tested proteins. The selected ITCs had no impact on NSCLC cell viability (at tested concentrations), but significantly decreased the cisplatin tolerance of cisplatin-resistant variant of A549 (A549CisR) and advanced (stage 4) NSCLC cell line H1581. Furthermore, long-term supplementation with ITC 1-(isothiocyanatomethyl)-4-phenylbenzene reverses the EMT phenotype and migratory potential of A549CisR to the level presented by parental A549 cells, increasing E-Cadherin expression, followed by decreased expression of ABCC1 and ALDH3A1. Our data indicates that the ALDH inhibitors DSF and ITCs are potential adjuvants of cisplatin chemotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available